Paclitaxel/Carboplatin Combination Achieves Encouraging Results In Breast Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Paclitaxel/Carboplatin Combination Achieves Encouraging Results In Breast Cancer

ROCHESTER, MN -- February 14, 2000 -- Mayo Clinic researchers report encouraging results with a new treatment for women with metastatic breast cancer. The researchers tested a combination of two drugs -- paclitaxel and carboplatin -- on 53 women. They reported a response rate (that is, evidence of tumor shrinkage) in 62 percent of the women and a projected one-year survival rate of 72 percent -- after follow-up ranging from 12 to 21 months. Edith Perez, M.D., an oncologist at Mayo Clinic in Jacksonville, FL., who led the multi-center study, said this is one of the highest response rates of any treatment for advanced breast cancer ever tested at Mayo Clinic.

She said this drug combination has been widely used in the treatment of ovarian and lung cancer but never before tried in breast cancer in the United States. "It's too early to know the long-term success of this treatment," she says. "But these early results are encouraging enough to serve as the basis for a number of new initiatives with this drug combination, both at Mayo Clinic and elsewhere."

One of the advantages of the new treatment, according to Dr. Perez, is that it is compatible with prior treatment with anthracycline, a drug commonly given to many women in the past for recurrent breast cancer. "This new combination is an additional therapy that adds additional benefits for these women," she says. The report appeared in a recent issue of the journal Cancer.

About 185,000 women are diagnosed with breast cancer every year. About ten percent have metastatic disease at the time of diagnosis, and about 40-50 percent of the others eventually develop metastatic disease, according to Dr. Perez.

Related Links: paclitaxel and carboplatin.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities